Research Topics
| Jose R ArribasSummaryCountry: Spain Publications
| Collaborators
|
Detail Information
Publications
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mlJose R Arribas
Hospital La Paz, Madrid, Spain
AIDS 24:223-30. 2010..In virologically suppressed patients, darunavir-ritonavir (DRV/r) monotherapy could maintain virological suppression similarly to DRV/r and two nucleosides...- The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baselineJ R Arribas
University Hospital La Paz, IdiPAZ, Madrid, Spain
HIV Med 13:398-405. 2012..two nucleoside reverse transcriptase inhibitors (NRTIs) plus DRV/r at the primary 48-week analysis. The trial was continued to week 144 to assess the durability of the results... 
Imported Plasmodium falciparum malaria in HIV-infected patients: a report of two casesSilvia García-Bujalance
Department of Microbiology and Parasitology, La Paz University Hospital IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain
Malar J 11:136. 2012..Factors like drug interactions and the possible implication of anti-malarial therapy bioavailability are all especially interesting in HIV-malaria co-infections...- Immunological predictors of CD4+ T cell decline in antiretroviral treatment interruptionsElena Seoane
Laboratorio de Inmuno Biología Molecular, Hospital General Universitario Gregorio Maranon, Madrid, Spain
BMC Infect Dis 8:20. 2008..The aim was to identify predictive markers of CD4+ cell count declines to < 350/microL in CD4-guided antiretroviral treatment interruptions... 
[The "induction-maintenance" strategy]José R Arribas López
Consulta de Medicina Interna II, Unidad VIH, Hospital La Paz, Madrid, Espana
Enferm Infecc Microbiol Clin 26:8-11. 2008..However, rates of virological efficacy are lower than those achieved with the simplification strategy. Moreover, this trial demonstrates that LPV/r monotherapy may have major benefits in peripheral fat preservation...- [Role of the new molecules in antiretroviral therapy. Position of raltegravir]Jose R Arribas
Consulta de Medicina Interna II Unidad VIH, Hospital La Paz, Madrid, Espana
Enferm Infecc Microbiol Clin 26:53-9. 2008..The drug's unusual mechanism of action has reopened the possibility of a positive effect on latent HIV reservoirs... - Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine)Jose R Arribas
Servicio de Medicina Interna, Unidad VIH Hospital La Paz, Universidad Autonoma de Madrid, Madrid, Spain
Curr Opin HIV AIDS 4:507-12. 2009..This review focuses on the use of tipranavir/ritonavir, darunavir/ritonavir and etravirine for the treatment of HIV infection that has become resistant to protease inhibitors and/or nonnucleoside reverse transcriptase inhibitors... - [Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker]José R Arribas López
Consulta de Medicina Interna II, Unidad VIH, Hospital La Paz, Madrid, Espana
Enferm Infecc Microbiol Clin 26:23-7. 2008..However, long-term follow up is required on patients treated with to be able to rule out any increased susceptibility to infections or neoplasms... - Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppressionFederico Pulido
Unidad VIH, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
Antivir Ther 14:195-201. 2009..Risk factors for loss of virological response in patients receiving lopinavir/ritonavir (LPV/r) monotherapy as maintenance treatment have not been determined... - Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIVFederico Pulido
Unidad HIV and Laboratorio de Microbiología Molecular, Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
AIDS 22:F1-9. 2008..Prior attempts to reduce the number of drugs needed to maintain viral suppression in patients with suppressed HIV replication while receiving three antiretroviral drugs have been unsuccessful... - Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppressionFederico Pulido
Unidad HIV, Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
J Antimicrob Chemother 61:1359-61. 2008..Data are scarce on the long-term efficacy of lopinavir/ritonavir monotherapy for the maintenance of HIV suppression. Four years of results of patients randomized to monotherapy in the Only Kaletra (OK) pilot clinical trial are presented... - Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study)Federico Pulido
HIV Unit, Hospital 12 de Octubre, Complutense University School of Medicine, Madrid, Spain
J Acquir Immune Defic Syndr 35:343-50. 2004..To compare the clinical, immunologic, and virologic outcomes of efavirenz (EFV)-based versus protease inhibitor (PI)-based highly active antiretroviral therapy (HAART) in severely immunosuppressed HIV-1-infected patients... - Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapyFederico Pulido
HIV Unit, Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
Antivir Ther 16:59-65. 2011..When patients have HIV RNA suppressed to <50 copies/ml on current treatment, switching to darunavir (DRV)/ritonavir (DRV/r) monotherapy could prevent the development of resistance to other drug classes... - Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysisJose R Arribas
Servicio de Medicina Interna, Hospital La Paz, Universidad Autonoma de Madrid, Madrid, Spain
J Acquir Immune Defic Syndr 51:147-52. 2009..However, it is still uncertain if this experimental strategy can maintain suppression in the long term... - Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903Juan Berenguer
Hospital Gregorio Maranon, Madrid, Spain
Clin Infect Dis 47:1083-92. 2008..The combination of didanosine, lamivudine, and efavirenz (ddI/3TC/EFV) for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection has been insufficiently analyzed in clinical trials... - Lipid and apoprotein profile in HIV-1-infected patients after CD4-guided treatment interruptionElena Seoane
Laboratorio de Inmuno Biología Molecular, Hospital General Universitario Gregorio Maranon, Madrid, Spain
J Acquir Immune Defic Syndr 48:455-9. 2008..The aims of the present study were to determine if metabolic abnormalities and cytokine derangements are modified in HIV-1-infected patients after 12 months on treatment interruption (TI)... - Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysisJose R Arribas
Internal Medicine Service, Hospital de La Paz, Madrid, Spain
J Acquir Immune Defic Syndr 47:74-8. 2008..As antiretroviral regimens for the treatment of HIV infection improve, trials providing data on long-term follow-up are increasingly important... - Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)Jose R Arribas
Hospital La Paz, Consulta de Medicina Interna II, Paseo de la Castellana, 28046 Madrid, Spain
J Acquir Immune Defic Syndr 40:280-7. 2005..This study evaluated maintenance with lopinavir/ritonavir monotherapy vs. continuing lopinavir/ritonavir and 2 nucleosides in HIV-infected patients with suppressed HIV replication... - Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factorsMaria Luisa Montes
Internal Medicine Service, La Paz Hospital, , Madrid, Spain
J Antimicrob Chemother 55:800-4. 2005..Antiretroviral-naive patients coinfected with hepatitis C have a low risk of developing hyperlipidaemia after starting lopinavir/ritonavir... - HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time of liver biopsyJosé F Pascual-Pareja
Servicio de Medicina Interna, Hospital La Paz, Paseo de la Castellana 261, Madrid 28046, Spain
AIDS 23:971-5. 2009..To evaluate the impact of HAART on the liver damage of HIV-hepatitis C virus (HCV)-coinfected patients with relatively preserved immune status... - Protease inhibitor monotherapyIgnacio Pérez-Valero
Servicio de Medicina Interna, Unidad VIH Hospital La Paz, IdiPAZ Madrid, Spain
Curr Opin Infect Dis 24:7-11. 2011..The present review focuses on recent data about boosted protease inhibitor monotherapy for maintenance of HIV virological suppression... - Protease inhibitor monotherapy: what is its role?Miriam Estébanez
Servicio de Medicina Interna, Unidad VIH Hospital La Paz, IdiPAZ, Madrid, Spain
Curr HIV/AIDS Rep 9:179-85. 2012..Some of the uncertainties possibly associated with protease inhibitor monotherapy such as the increased risk of neurological events and a higher level of subclinical inflammation will be discussed in this review... - High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients)Jose R Arribas
Internal Medicine Service, La Paz Hospital, , Madrid, Spain
AIDS 16:1554-6. 2002..Efavirenz-based HAART was found to be effective in profoundly immunosuppressed HIV-1-infected patients... - Protease inhibitor monotherapy and the CNS: peace of mind?Ignacio Pérez-Valero
Servicio de Medicina Interna, Unidad VIH, Hospital La Paz, IdiPAZ, Madrid, Spain
J Antimicrob Chemother 66:1954-62. 2011..It is clear that more studies including detailed neurocognitive testing are needed to completely establish the risk/benefit ratio of bPI monotherapy or triple-drug HAART for preserving neurocognitive function in HIV-infected patients... - Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized studyMaria Jesús Pérez-Elías
Infectious Diseases Service, Clinical Research Department, Ramon y Cajal Hospital, Madrid, Spain
Antivir Ther 8:577-84. 2003..Resistance testing is useful in the management of virological failure patients, although the best method to be used in clinical practice has not been determined... - Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2004 [correction]Juan Berenguer
Unidad de Enfermedades Infecciosas, Hospital General Gregorio Maranon, Madrid, Spain
Enferm Infecc Microbiol Clin 22:160-76. 2004..To provide an update of guidelines from the Spanish AIDS Study Group (GESIDA) and the National AIDS Plan (PNS) committee on the prevention of opportunistic infections in adult and adolescent HIV-infected patients... - Is etravirine and two nucleosides an option for HIV with an isolated K103N mutation?Miriam Estébanez
HIV Unit, Internal Medicine Service bMicrobiology Service Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
AIDS 27:141-4. 2013..In three patients tested, the K103N mutation was detected in cellular HIV-1 DNA whereas remaining suppressed on etravirine plus tenofovir/emtricitabine... - Updating our understanding of pulmonary disease associated with HIV infectionMiriam Estébanez-Muñoz
Unidad de VIH, Servicio de Medicina Interna, Hospital Universitario La Paz, IdiPAZ, Madrid, Espana
Arch Bronconeumol 48:126-32. 2012..The aim of this paper is to review the most innovative and relevant aspects of lung pathology in patients infected with HIV...